CA14161Y2006
© PR Newswire
16.01.2026
CRDL
LISTED
TSX
Canadian Investment Regulatory Organization Trade Resumption - CRDL
News Preview
TORONTO, Jan. 16, 2026 /CNW/ - Trading resumes in:
Company: Cardiol Therapeutics Inc.TSX Symbol: CRDLAll Issues: YesResumption (ET): 9:00 AMCIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. CIRO is the national s...
Themefolio
Profiler
Peergroup
© Newsfile
16.01.2026
CRDL
LISTED
TSX
Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million
News Preview
Toronto, Ontario--(Newsfile Corp. - January 16, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that it has entered into an agreement with a sole under...
Themefolio
Profiler
Peergroup
© Newsfile
16.01.2026
CRDL
LISTED
TSX
Cardiol Therapeutics Inc. Announces Bought Deal Financing for Gross Proceeds of $13.5 Million
News Preview
Toronto, Ontario--(Newsfile Corp. - January 16, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that it has entered into an agreement with Canaccord Ge...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© PR Newswire
16.01.2026
CRDL
LISTED
TSX
Canadian Investment Regulatory Organization Trading Halt - CRDL
News Preview
TORONTO, Jan. 16, 2026 /CNW/ - The following issues have been halted by CIRO:
Company: Cardiol Therapeutics Inc.TSX Symbol: CRDL All Issues: YesReason: Pending News Halt Time (ET): 8:10 AMCIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Newsfile
13.01.2026
CRDL
LISTED
TSX
Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
News Preview
Clinical trial infrastructure fully operational in the U.S. with more than 15 leading cardiovascular centers actively enrolling patients.Activation of additional top-tier clinical sites in Europe and Canada underway, further accelerating enrollment momentum.Full enrollment expected in Q2 2026.Toronto, Ontario--(Newsfile Corp. - January 13, 2026) -...
Themefolio
Profiler
Peergroup
© EQS Newswire
17.12.2025
CRDL
LISTED
TSX
First Berlin Equity Research GmbH: Cardiol Therapeutics Inc | Rating: BUY
News Preview
Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
17.12.2025 / 14:38 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to co......
Themefolio
Profiler
Peergroup
© Newsfile
01.12.2025
CRDL
LISTED
TSX
New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions
News Preview
Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac MRI (CMR) measures of structural heart recovery in patients with acute myocarditis.Results provide clinical evidence that CardiolRx™ reduces inflammation-driven structural damage in the heart, an important cau...
Themefolio
Profiler
Peergroup
© Newsfile
13.11.2025
CRDL
LISTED
TSX
Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040
News Preview
Once issued, this new U.S. patent covers the use of CardiolRx™ and CRD-38 for a broad range of cardiac disorders, including atherosclerosis and heart failure, significantly expanding intellectual property protection in the world's largest pharmaceutical market.This allowance fortifies Cardiol's global intellectual property portfolio, adding t...
Themefolio
Profiler
Peergroup
© Newsfile
05.11.2025
CRDL
LISTED
TSX
Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases
News Preview
The ESC M&PD meeting brings together the world's experts working to improve the treatment of myocarditis and pericarditis.Presentation to provide comprehensive findings from the ARCHER trial following the reporting of topline results demonstrating a notable improvement in extracellular volume and a significant reduction in left ventricular mass...
Themefolio
Profiler
Peergroup
© EQS Newswire
23.10.2025
CRDL
LISTED
TSX
First Berlin Equity Research GmbH: Cardiol Therapeutics Inc | Rating: BUY
News Preview
Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
23.10.2025 / 12:51 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to co......
Themefolio
Profiler
Peergroup
© Newsfile
21.10.2025
CRDL
LISTED
TSX
Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027
News Preview
MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx™ in recurrent pericarditis is fully funded through to a planned New Drug Application submission with the FDA.New data from the ARCHER trial, highlighting the magnitude of reduction in left ventricular (LV) mass and the read through to heart failure, to be presented at a cardio...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
CRDL
LISTED
TSX
Canadian Investment Regulatory Organization Trade Resumption - CRDL
News Preview
TORONTO, Oct. 20, 2025 /CNW/ - Trading resumes in:
Company: Cardiol Therapeutics Inc.
TSX Symbol: CRDL
All Issues: Yes
Resumption (ET): 8:00 AM
CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-liste...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Newsfile
17.10.2025
CRDL
LISTED
TSX
Cardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into Q3 2027
News Preview
MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx™ in recurrent pericarditis is fully funded through to a planned New Drug Application submission with the FDA.New data from the ARCHER trial, highlighting the magnitude of reduction in left ventricular (LV) mass and the read through to heart failure, to be presented at a cardio...
Themefolio
Profiler
Peergroup
© PR Newswire
17.10.2025
CRDL
LISTED
TSX
Canadian Investment Regulatory Organization Trading Halt - CRDL
News Preview
TORONTO, Oct. 17, 2025 /CNW/ - The following issues have been halted by CIRO:
Company: Cardiol Therapeutics Inc.
TSX Symbol: CRDL
All Issues: Yes
Reason: Pending News
Halt Time (ET): 4:12 PM
CIRO can make a decision to impose a temporar...
Themefolio
Profiler
Peergroup
© EQS Newswire
12.08.2025
CRDL
LISTED
TSX
First Berlin Equity Research GmbH: Cardiol Therapeutics Inc | Rating: BUY
News Preview
Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
12.08.2025 / 13:31 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to co......
Themefolio
Profiler
Peergroup
© Newsfile
11.08.2025
CRDL
LISTED
TSX
Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference
News Preview
Toronto, Ontario--(Newsfile Corp. - August 11, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that it will participate in a Fireside Chat at...
Themefolio
Profiler
Peergroup
© Newsfile
22.07.2025
CRDL
LISTED
TSX
Cardiol Therapeutics Announces Database Lock for Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis
News Preview
ARCHER is designed to assess the impact of CardiolRx™ on cardiac magnetic resonance imaging parameters that measure heart dysfunction and edema/fibrosis-key measurements used to predict prognosis in myocarditis patients.Acute myocarditis is a potentially life-threatening condition affecting the heart muscle (myocardium) and is characterized b...
Themefolio
Profiler
Peergroup
© Newsfile
29.05.2025
CRDL
LISTED
TSX
Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders
News Preview
Toronto, Ontario--(Newsfile Corp. - May 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces the results from its Annual General Meeting of Shareholders (t...
Themefolio
Profiler
Peergroup
© Newsfile
27.05.2025
CRDL
LISTED
TSX
Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on May 28th at 4:30 p.m. EDT
News Preview
Toronto, Ontario--(Newsfile Corp. - May 27, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces that the Company's virtual Annual General Meeting of Sharehold...
Themefolio
Profiler
Peergroup
© Newsfile
29.04.2025
CRDL
LISTED
TSX
Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors
News Preview
Former Chief Medical Officer of Eli Lilly brings more than thirty years of pharmaceutical industry experienceToronto, Ontario--(Newsfile Corp. - April 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapi...
Themefolio
Profiler
Peergroup
© EQS Newswire
23.04.2025
CRDL
LISTED
TSX
First Berlin Equity Research GmbH: Cardiol Therapeutics Inc | Rating: Buy
News Preview
Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
23.04.2025 / 15:24 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to co......
Themefolio
Profiler
Peergroup
© Newsfile
16.04.2025
CRDL
LISTED
TSX
Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
News Preview
Designed to assess the impact of CardiolRx™ on preventing episodes of recurrent pericarditis, the first patient has been randomized by Northwestern University in Chicago.Based on a successful end-of-Phase II meeting with the US FDA and subject to MAVERIC outcomes, Cardiol believes the results from MAVERIC will support a New Drug Application.D...
Themefolio
Profiler
Peergroup
© Newsfile
01.04.2025
CRDL
LISTED
TSX
Cardiol Therapeutics Announces Year-End 2024 Update on Operations
News Preview
Reported positive data from the Phase II MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis; results support advancing to the Phase III MAVERIC trialCompleted patient enrollment in the Phase II ARCHER trial evaluating CardiolRx™ in patientswith acute myocarditis, w...
Themefolio
Profiler
Peergroup
© Newsfile
03.03.2025
CRDL
LISTED
TSX
Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
News Preview
Toronto, Ontario--(Newsfile Corp. - March 3, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that it will present at the TD Cowen 45th Annual...
Themefolio
Profiler
Peergroup
© Newsfile
20.02.2025
CRDL
LISTED
TSX
Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failur
News Preview
Data demonstrates improvement in cardiac function and reductions in cardiac hypertrophy, remodeling, inflammation, and cell death - key underlying mechanisms in heart failureToronto, Ontario--(Newsfile Corp. - February 20, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences compa...
Themefolio
Profiler
Peergroup
© Newsfile
04.02.2025
CRDL
LISTED
TSX
Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
News Preview
Toronto, Ontario--(Newsfile Corp. - February 4, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that it will pr...
Themefolio
Profiler
Peergroup
© EQS Newswire
22.11.2024
CRDL
LISTED
TSX
First Berlin Equity Research GmbH: Cardiol Therapeutics Inc | Rating: BUY
News Preview
Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
22.11.2024 / 11:05 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to......
Themefolio
Profiler
Peergroup
© Newsfile
18.11.2024
CRDL
LISTED
TSX
Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024
News Preview
Marked and rapid reductions in both pericarditis pain and inflammation maintained throughout the 26-week studyEpisodes of pericarditis per year substantially reduced MAvERIC-Pilot results support advancing CardiolRx™ into the Phase II/III MAVERIC-2and the Phase III MAVERIC-3 clinical trialsToronto, Ontario--(Newsfile Corp. - November 18...
Themefolio
Profiler
Peergroup
© EQS Newswire
28.10.2024
CRDL
LISTED
TSX
First Berlin Equity Research GmbH: Cardiol Therapeutics Inc | Rating: Buy
News Preview
Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
28.10.2024 / 15:45 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to......
Themefolio
Profiler
Peergroup
© Newsfile
22.10.2024
CRDL
LISTED
TSX
Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis
News Preview
MAVERIC-2 trial will evaluate the impact of CardiolRx(TM) following cessation of interleukin-1 blocker therapy (rilonacept or anakinra) and is expected to run concurrently with the Company's planned Phase III program.Toronto, Ontario--(Newsfile Corp. - October 22, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Compa...
Themefolio
Profiler
Peergroup
© Newsfile
11.10.2024
CRDL
LISTED
TSX
Cardiol Therapeutics Announces Exercise and Closing of Over-Allotment Option
News Preview
Oakville, Ontario--(Newsfile Corp. - October 11, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that, further...
Themefolio
Profiler
Peergroup
© Newsfile
10.10.2024
CRDL
LISTED
TSX
Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares
News Preview
Oakville, Ontario--(Newsfile Corp. - October 10, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, confirmed today that it has successfu...
Themefolio
Profiler
Peergroup
© Newsfile
09.10.2024
CRDL
LISTED
TSX
Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares
News Preview
Oakville, Ontario--(Newsfile Corp. - October 9, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announced today the pricing of its pre...
Themefolio
Profiler
Peergroup
© Newsfile
08.10.2024
CRDL
LISTED
TSX
Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares
News Preview
Toronto, Ontario--(Newsfile Corp. - October 8, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce the Company has...
Themefolio
Profiler
Peergroup
© Newsfile
24.09.2024
CRDL
LISTED
TSX
Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx(TM) for Acute Myocarditis
News Preview
Toronto, Ontario--(Newsfile Corp. - September 24, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced it has achieved the...
Themefolio
Profiler
Peergroup
© Newsfile
10.09.2024
CRDL
LISTED
TSX
Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024
News Preview
Full clinical data will be reported in an oral presentation at the premier global event for advancements in cardiovascular science and medicine on November 18, 2024Toronto, Ontario--(Newsfile Corp. - September 10, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focuse...
Themefolio
Profiler
Peergroup
© Newsfile
27.06.2024
CRDL
LISTED
TSX
Cardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of Shareholders
News Preview
Toronto, Ontario--(Newsfile Corp. - June 27, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces the results from its annual gen...
Themefolio
Profiler
Peergroup
© Newsfile
25.06.2024
CRDL
LISTED
TSX
Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting of Shareholders on June 26th at 4:30 p.m. EDT
News Preview
Toronto, Ontario--(Newsfile Corp. - June 25, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces that the Company's virtual Annu...
Themefolio
Profiler
Peergroup
© EQS Newswire
14.06.2024
CRDL
LISTED
TSX
First Berlin Equity Research GmbH: Cardiol Therapeutics Inc | Rating: Buy
News Preview
Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
Classification of First Berlin Equity Research GmbH to Cardiol Therapeutics Inc
Company Name: Cardiol Therapeutics Inc
ISIN: CA14161Y2006
Reason for the research: Update
Recommendation: Buy
from: 14.06.2024
Target price: USD8.50
Target price on sight of: 12 months......
Themefolio
Profiler
Peergroup
© Newsfile
13.06.2024
CRDL
LISTED
TSX
Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
News Preview
Administration of CardiolRx™ led to a marked reduction in the primary efficacy endpoint of pericarditis painCardiolRx™ also shown to reduce inflammation in patients with elevated CRP89% of patients have continued into the extension phase of the studyToronto, Ontario--(Newsfile Corp. - June 13, 2024) - Cardiol Therapeutics Inc. (NASDAQ:...
Themefolio
Profiler
Peergroup
© Newsfile
14.05.2024
CRDL
LISTED
TSX
Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024
News Preview
Scope of presentation included trial design, rationale, and blinded baseline data on first 50 patients randomized into the Phase II study evaluating CardiolRx™ in patients with acute myocarditis ARCHER trial rationale and design also accepted for publication in the journal ESC Heart FailureARCHER trial has now exceeded 85% of target patient e...
Themefolio
Profiler
Peergroup
© Newsfile
02.04.2024
CRDL
LISTED
TSX
Cardiol Therapeutics Announces Year-End 2023 Update on Operations
News Preview
Completed patient enrollment in the Phase II MAvERIC-Pilot study evaluating CardiolRx™ in patients withrecurrent pericarditis, with topline results expected in Q2 2024CardiolRx™ granted U.S. FDA Orphan Drug Designation for the treatment of pericarditis,which includes recurrent pericarditisExceeded 50% enrollment in the Phase II ARCHER t...
Themefolio
Profiler
Peergroup
© EQS Newswire
27.02.2024
CRDL
LISTED
TSX
First Berlin Equity Research GmbH: Cardiol Therapeutics Inc | Rating: Buy
News Preview
Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
Classification of First Berlin Equity Research GmbH to Cardiol Therapeutics Inc
Company Name: Cardiol Therapeutics Inc
ISIN: CA14161Y2006
Reason for the research: Update
Recommendation: Buy
from: 27.02.2024
Target price: USD 3.60
Target price on sight of: 12 month......
Themefolio
Profiler
Peergroup
© Newsfile
21.02.2024
CRDL
LISTED
TSX
Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
News Preview
Topline Results Expected in Q2 2024This is a Designated News Release.Toronto, Ontario--(Newsfile Corp. - February 21, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for...
Themefolio
Profiler
Peergroup
© Newsfile
15.02.2024
CRDL
LISTED
TSX
Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis
News Preview
Designation Based on Pre-Clinical Data and Initial Clinical Data from the Company's MAvERIC-Pilot Phase II StudyThis is a Designated News Release.Toronto, Ontario--(Newsfile Corp. - February 15, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research a...
Themefolio
Profiler
Peergroup
© Newsfile
24.01.2024
CRDL
LISTED
TSX
Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital Market
News Preview
Toronto, Ontario--(Newsfile Corp. - January 24, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced that it received notic...
Themefolio
Profiler
Peergroup
© EQS Newswire
19.01.2024
CRDL
LISTED
TSX
First Berlin Equity Research GmbH: Cardiol Therapeutics Inc | Rating: Buy
News Preview
Original-Research: Cardiol Therapeutics Inc - von First Berlin Equity Research GmbH
Einstufung von First Berlin Equity Research GmbH zu Cardiol Therapeutics Inc
Unternehmen: Cardiol Therapeutics Inc
ISIN: CA14161Y2006
Anlass der Studie: Update
Empfehlung: Buy
seit: 19.01.2024
Kursziel: USD 3.60
Kursziel auf Sicht von: 12 months
Letzte Ratingänderu......
Themefolio
Profiler
Peergroup
© Newsfile
09.01.2024
CRDL
LISTED
TSX
Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis
News Preview
Toronto, Ontario--(Newsfile Corp. - January 9, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that it has exce...
Themefolio
Profiler
Peergroup
© Newsfile
05.12.2023
CRDL
LISTED
TSX
Cardiol Therapeutics Announces Massachusetts General Hospital, Largest Teaching Hospital of Harvard Medical School, as the 8th Major Medical Centre Participating in MAvERIC-Pilot
News Preview
MAvERIC-Pilot is a Phase II Study in Recurrent Pericarditis and is Anticipated to Complete Patient Recruitment during Q1 2024Toronto, Ontario--(Newsfile Corp. - December 5, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical developmen...
Themefolio
Profiler
Peergroup
© Newsfile
16.11.2023
CRDL
LISTED
TSX
Cardiol Therapeutics Announces Study Results Presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases
News Preview
Toronto, Ontario--(Newsfile Corp. - November 16, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announced today that study results de...
Themefolio
Profiler
Peergroup
© Newsfile
01.11.2023
CRDL
LISTED
TSX
Cardiol Therapeutics Announces It Has Exceeded 50% Enrollment in Its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis
News Preview
Toronto, Ontario--(Newsfile Corp. - November 1, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that it has exc...
Themefolio
Profiler
Peergroup
© Newsfile
20.10.2023
CRDL
LISTED
TSX
Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
News Preview
Toronto, Ontario--(Newsfile Corp. - October 20, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces that on October 19, 2023, it...
Themefolio
Profiler
Peergroup
© Newsfile
10.10.2023
CRDL
LISTED
TSX
Cardiol Therapeutics Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in a Model of Heart Failure with Preserved Ejection Fraction
News Preview
Results Demonstrate the Active Pharmaceutical Ingredient in Cardiol's Novel CRD-38 Formulation Attenuates Harmful Fat Distribution and Key Markers of Cardiac Inflammation and RemodellingData Presented at the Heart Failure Society of America Annual Scientific Meeting 2023 Toronto, Ontario--(Newsfile Corp. - October 10, 2023) - Cardiol Therapeutics I...
Themefolio
Profiler
Peergroup
© Newsfile
26.09.2023
CRDL
LISTED
TSX
Cardiol Therapeutics to Present at Cantor Fitzgerald 2023 Global Healthcare Conference
News Preview
Toronto, Ontario--(Newsfile Corp. - September 26, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that Cardiol'...
Themefolio
Profiler
Peergroup
© Newsfile
19.09.2023
CRDL
LISTED
TSX
Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in ARCHER, a Phase II Trial of CardiolRx(TM) for the Treatment of Acute Myocarditis
News Preview
Recruitment Accelerating and Full Patient Enrollment Anticipated to be Completed During Q3 2024, up to Six Months Ahead of Schedule Multi-Center, International, Double-blind, Placebo-controlled Trial Randomizing 100 PatientsToronto, Ontario--(Newsfile Corp. - September 19, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol"...
Themefolio
Profiler
Peergroup
© Newsfile
09.08.2023
CRDL
LISTED
TSX
Cardiol Therapeutics to Present at Canaccord Genuity 43rd Annual Growth Conference
News Preview
Toronto, Ontario--(Newsfile Corp. - August 9, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that Cardiol's Pr...
Themefolio
Profiler
Peergroup
© Newsfile
08.08.2023
CRDL
LISTED
TSX
Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital Market
News Preview
Oakville, Ontario--(Newsfile Corp. - August 8, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced that it received notice...
Themefolio
Profiler
Peergroup
© Newsfile
29.06.2023
CRDL
LISTED
TSX
Cardiol Therapeutics Reports Results of 2023 Annual General Meeting
News Preview
Oakville, Ontario--(Newsfile Corp. - June 29, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces the results from its Annual Ge...
Themefolio
Profiler
Peergroup
© Newsfile
27.06.2023
CRDL
LISTED
TSX
Cardiol Therapeutics to Webcast Virtual Annual General Meeting on June 28th at 4:30 p.m. EDT
News Preview
Oakville, Ontario--(Newsfile Corp. - June 27, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today is pleased to announce that the Co...
Themefolio
Profiler
Peergroup
© Newsfile
29.03.2023
CRDL
LISTED
TSX
Cardiol Therapeutics Announces Year-End 2022 Update on Operations
News Preview
Initiated patient enrollment in a Phase II open-label clinical trial investigating the safety, tolerability, and efficacy of CardiolRx™ in patients with recurrent pericarditis - a debilitating heart disease associated with chest pain, shortness of breath and fatigue, resulting in markedly reduced quality of life, emergency department visits,...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
